MA41172B1 - Tetrahydro-pyrido [3,4-b] indoles as estrogen receptor modulators and their uses - Google Patents

Tetrahydro-pyrido [3,4-b] indoles as estrogen receptor modulators and their uses

Info

Publication number
MA41172B1
MA41172B1 MA41172A MA41172A MA41172B1 MA 41172 B1 MA41172 B1 MA 41172B1 MA 41172 A MA41172 A MA 41172A MA 41172 A MA41172 A MA 41172A MA 41172 B1 MA41172 B1 MA 41172B1
Authority
MA
Morocco
Prior art keywords
estrogen receptor
pyrido
tetrahydro
compounds
receptor modulators
Prior art date
Application number
MA41172A
Other languages
French (fr)
Inventor
Daniel Fred Ortwine
Jun Li
Xiaojing Wang
Zhiguo Liu
Sharada Labadie
Kwong Wah Lai
Nicholas Charles Ray
Simon Charles Goodacre
Jun Liang
Birong Zhang
Jason Zbieg
Tao Wang
Jiangpeng Liao
John Sui-Man Wai
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/EP2015/080119 external-priority patent/WO2016097072A1/en
Publication of MA41172B1 publication Critical patent/MA41172B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de tétrahydro-pyrido[3,4-b]indol-1-yl dotés d'une activité ou d'une fonction de modulation des récepteurs des œstrogènes, ces composés présentant une structure de formule (i), ainsi que des stéréoisomères, des tautomères ou des sels pharmaceutiquement acceptables de ceux-ci, et leurs substituants et caractéristiques structurelles. La présente invention concerne également des compositions pharmaceutiques et des médicaments contenant lesdits composés de formule (i), ainsi que des méthodes d'utilisation desdits modulateurs des récepteurs des œstrogènes, seuls ou en association avec d'autres agents thérapeutiques, dans le traitement de maladies ou d'affections induites par les récepteurs des oestrogènes ou qui en dépendent.The invention relates to tetrahydro-pyrido [3,4-b] indol-1-yl compounds having estrogen receptor modulating activity or function, said compounds having a structure of formula (i), as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof, and their substituents and structural characteristics. The present invention also relates to pharmaceutical compositions and medicaments containing said compounds of formula (i), as well as to methods of using said estrogen receptor modulators, alone or in combination with other therapeutic agents, in the treatment of diseases. or disorders induced or dependent on estrogen receptors.

MA41172A 2014-12-18 2015-12-17 Tetrahydro-pyrido [3,4-b] indoles as estrogen receptor modulators and their uses MA41172B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093929P 2014-12-18 2014-12-18
PCT/EP2015/080119 WO2016097072A1 (en) 2014-12-18 2015-12-17 TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Publications (1)

Publication Number Publication Date
MA41172B1 true MA41172B1 (en) 2020-09-30

Family

ID=58672209

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41172A MA41172B1 (en) 2014-12-18 2015-12-17 Tetrahydro-pyrido [3,4-b] indoles as estrogen receptor modulators and their uses

Country Status (2)

Country Link
AR (2) AR103081A1 (en)
MA (1) MA41172B1 (en)

Also Published As

Publication number Publication date
AR103081A1 (en) 2017-04-12
AR122456A2 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
MA42295B1 (en) Benzoxazepin oxazolidinone compounds and method for their use
PH12017501140A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
MA37762A1 (en) N-aryltriazole compounds used as antagonists of lpar
MA37400B1 (en) Heterocyclyl compounds as mek inhibitors
MA37764A1 (en) N-alkyltriazole compounds used as antagonists of lpar
TN2014000420A1 (en) INDOLE AND INDAZOLE DERIVATIVES THAT ACTIVATE MPK
MA40290A1 (en) Immune-regulating agents
MA38380A1 (en) Quinazoline inhibitors of activation of mutant forms of epidermal growth receptor (EGFR)
MA43979B1 (en) 1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders
MA38483A1 (en) Inhibitors of ido
MA41179A (en) PARG INHIBITOR COMPOUNDS
MA33734B1 (en) N1-PYRAZOLOSPIROCETONE ACETYL-COA CARBOXYLASE INHIBITORS
MA40955B1 (en) 2-amino-6- (difluoromethyl) -5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MA37891A1 (en) Alcoxypyrazoles as activators of soluble guanylate cyclase
TN2013000393A1 (en) PYRAZOLOSPIROCETONE DERIVATIVES FOR USE AS INHIBITORS OF ACETYL-COA CARBOXYLASE
MA38648B1 (en) Carboxamide compounds of substituted carbazole and tetrahydrocarbazole suitable as kinase inhibitors
MA46229B1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MA37765A1 (en) Substituted pyrazole compounds used as lpar antagonists
MA38810B1 (en) Inhibitors of rorc2 related methods of use
MA41988B1 (en) Azabenzimidazoles and their use as ampa receptor modulators
MA39165A1 (en) Benzimidazole-proline derivatives for their use in the treatment of crepuscular state syndrome
MA39229A1 (en) Pyrrolidines, terrahydrofurans and substituted cyclopentanes useful as orexin receptor antagonists
MA41172B1 (en) Tetrahydro-pyrido [3,4-b] indoles as estrogen receptor modulators and their uses
MA50457B1 (en) PYRIDINE CARBONYL DERIVATIVES AND THEIR THERAPEUTIC USES AS TRPC6 INHIBITORS
EA202192092A2 (en) TETRAHYDROPIRIDO [3,4-b] INDOLIC ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION